Takeda announces takeover of TiGenix

Takeda has agreed a deal to purchase the biopharmaceutical company TiGenix in a deal worth approximately EUR 520 million (GBP 460.65 million).

TiGenix is dedicated to developing novel stem cell therapies for serious medical conditions and has been working with Takeda to bring new treatment options to patients with gastrointestinal disorders.

This acquisition will build on the companies' existing work to develop and commercialise Cx601, which has already been recommended for European regulatory approval for the treatment of complex perianal fistulas in Crohn's disease.

It is expected that the deal will expand Takeda's late-stage gastroenterology pipeline, particularly in the field of inflammatory bowel disease therapies, while also strengthening its presence in the US specialty care market.

Andrew Plump, chief medical and scientific officer at Takeda, said: "I have had the opportunity to work alongside the TiGenix team throughout our collaboration and know that we have shared goals and varied but complementary expertise."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.